1 big reason to buy CSL shares now

Goldman Sachs is saying good things about this blue chip stock.

| More on:
A young woman drinking coffee in a cafe smiles as she checks her phone.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you have been thinking about buying CSL Ltd (ASX: CSL) shares, then read on.

That's because Goldman Sachs has just named another reason to buy the biotechnology giant's shares.

Why are CSL shares a buy?

Goldman notes that both the Australian Therapeutic Goods Administration (TGA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) have approved the registration of ANDEMBRY (garadacimab) for routine prevention of recurrent hereditary angiodema (HAE) attacks.

It highlights that the approvals in Australia and the UK are the first regions in the world for garadacimab but aren't likely to be the last.

That's because the therapy is also under review by regulatory agencies in the United States (US), European Union (EU) and Japan. Goldman appears confident that approvals are on the way. It said:

In our view, approvals by the TGA and MHRA reinforce garadacimab's strong clinical profile as reflected in the pivotal placebo-controlled Phase 3 VANGUARD trial and should support US and EU approvals. CSL has guided to FDA and EU approvals by 30 June 2025 and our FY26 forecasts reflect ~$250m of garadacimab sales.

Commercial opportunity

Approvals in the EU and US would be good news for CSL and its shares. That's because Goldman sees potential for garadacimab to deliver a big contribution to its sales in the near term and help claw back lost market share. It explains:

Over the last 5 years (CY19-CY24), we estimate CSL has lost ~700bps in HAE market share following the launches of TAKHZYRO and ORLADEYO. The introduction of garadacimab provides the opportunity to regain some share and grow the prophylactic HAE market, given its more convenient dosing schedule (once monthly). Our CSL HAE revenue growth forecast of 25% FY25-FY28 CAGR reflects ~27% market share by the end of this period which compares to CSL's target of 30%.

In response to the news, Goldman has reaffirmed its buy rating and $325.40 price target on CSL's shares. This implies potential upside of 19% for investors over the next 12 months. It adds:

Over the last 10 years, CSL's premium to the ASX 200 has ranged from 1.5x-3.0x. We adopt a premium of 1.8x as part of our valuation which is close to the 10-year average noting the current share price values the business cheaper relative to its 5 and 10-year averages. We believe ongoing momentum in CSL's IG revenue growth, Gross Margin recovery and execution on market share initiatives in Hemophilia and HAE are key drivers in driving re-rating.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Why is the Sigma share price soaring 6%?

Sigma has upgraded its FY25 guidance ahead of the anticipated Chemist Warehouse merger completion.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »

A person is weighed down by a huge stack of coins, they have received a big dividend payout.
Dividend Investing

Looking to bag the record high ResMed dividend? You better hurry!

Unlike the majority of ASX 200 income stocks, ResMed pays dividends every quarter.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

Read more »

Business people discussing project on digital tablet.
Healthcare Shares

Down 4%, is the ResMed share price in the buy zone?

Do analysts think investors should be buying the dip? Let's see what they are saying.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Guess which ASX 100 share is sinking 8% because of Trump's tariffs

Donald Trump has dealt this company a big blow. What's happening?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?

Mesoblast shares have surged more than 1,000% over the last 12 months.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Earnings Results

ResMed shares rise on strong Q2 result

Let's see how this sleep treatment company performed during the second quarter.

Read more »